Stubborn Fat: Non-Surgical Fat Reduction Options Compared

We found no single medical definition of stubborn fat; the closest thing to one on the American Academy of Dermatology's (AAD) patient page is its description of good candidates for non-invasive fat removal: people with a small bulge of fat that remains despite diet and exercise, whose weight falls within the normal range for their height.

The areas people mean show up in the device clearances themselves: the abdomen, the flanks (the clearance says “love handles”), upper arms, bra fat, back fat, the banana roll, the thighs, and the fullness under the chin.

Destroyed fat cells do not come back, the AAD says, but the fat cells left in the treated area can still expand if you gain weight.

Stubborn fat is not the same problem as cellulite.

The AAD says cellulite differs from fat, and treatments that effectively remove fat often have no effect on cellulite — the AAD does not recommend cryolipolysis for cellulite, and says liposuction is not recommended for it either and can make dimpling more obvious.

If dimpling rather than a bulge is the concern, start from our skin and body concerns hub instead.

Fat freezing — cryolipolysis — is the CoolSculpting category: a device chills a fat bulge until its cells break down.

The current CoolSculpting Elite system is FDA-cleared under 510(k) K233732, dated September 12, 2024, for cold-assisted lipolysis (breakdown of fat) of the upper arm, bra fat, back fat, banana roll, thigh, abdomen and flank in people with a BMI of 30 or less, and of the submental (under the chin) and submandibular (under the jawline) areas in people with a BMI up to 46.2.

FDA first cleared the technology in 2010 through a De Novo grant (DEN090002).

The device cools the treatment site to a target temperature as low as −11°C and automatically stops if the skin interface overshoots the target by more than 1°C when treating below 5°C.

The AAD's figure is usually 2 cryolipolysis sessions.

Results can start as early as 3 weeks, with the full effect 3 to 6 months after the last treatment.

What the studies show is a reduction in the treated bulge, not a transformation.

ASPS (the American Society of Plastic Surgeons) says the injured fat cells are gradually cleared by the body over four to six months, with an average fat reduction of about 20 percent in the treated bulge.

A 2015 systematic review of 19 cryolipolysis studies found average fat-layer reductions of 14.67% to 28.5% when measured by caliper and 10.3% to 25.5% by ultrasound, with mainly mild, short-term side effects.

Allergan, the maker, says in its own consumer safety information that CoolSculpting is not a treatment for weight loss, and that people with cryoglobulinemia, cold agglutinin disease or paroxysmal cold hemoglobinuria should not be treated.

ASPS adds a category-wide caution: people who are pregnant or breastfeeding should not have any of these procedures — it names cryolipolysis, injection lipolysis, radiofrequency and laser lipolysis.

The heat-based category works the opposite way from freezing: a laser or radiofrequency device heats fat through the skin.

The clearest example is SculpSure, a 1060-nm laser device from Cynosure that was first cleared on May 15, 2015 (K150230) for non-invasive lipolysis of the flanks in people with a BMI of 30 or less; later clearances expanded its areas.

Radiofrequency is the other heat-based option the AAD counts in this category, at 4 to 10 sessions.

Ultrasound devices are also in the AAD's list, at 1 to 3 sessions.

A separate group of low-level laser devices — marketed as “lipo laser”, for example Erchonia's Zerona — is cleared only for reduction of body circumference as a non-invasive aesthetic treatment, not for fat loss or weight loss.

The first was cleared in 2010 (De Novo DEN090008), and current Zerona models are cleared for over-the-counter use.

The evidence base is thin: a 2025 systematic review found only three randomized trials (160 participants), with waist circumference falling 2.48 cm with low-level laser treatment versus 0.64 cm in controls, and the authors noted varied protocols and unclear long-term efficacy.

Session count is one of the practical differences in this category: 4 to 10 radiofrequency visits is a different commitment from 2 freezing sessions.

In the injection category, the FDA-approved option this page covers is a prescription drug, and its approval is narrow.

Kybella (deoxycholic acid) is approved for moderate to severe fullness from submental fat — the double chin — in adults.

The label's own words: “KYBELLA is not approved for the treatment of subcutaneous fat outside the submental region, and such use is not recommended.” Jowls, bra fat or belly fat injections are therefore off-label.

The label allows up to 6 single treatments, at least 1 month apart.

The AAD describes chin-fat injection courses more typically as 2 sessions spaced 6 to 8 weeks apart; the label, not the AAD page, is the document that governs the drug.

Reactions in the treated area are common in the label's data.

In Kybella's pooled pivotal trials (513 treated people), swelling occurred in 87% (versus 43% on placebo), bruising in 72% (versus 70% on placebo), pain in 70%, numbness in 66%, redness in 27% and hardness in 23%.

The AAD adds that some people are extremely swollen for as long as 2 weeks, though they can return to normal activities, and that full results show about 3 to 4 months after the last treatment.

Before treating, the label tells providers to screen for other causes of under-chin fullness, such as an enlarged thyroid or swollen lymph nodes, and to weigh the risks in people with excess skin laxity or prominent platysmal bands, where results may not look good.

Kybella's pivotal trials enrolled adults aged 19 to 65 with a BMI of 40 or less.

Two cautions about the wider “fat injection” market.

The FDA recommends against dermal fillers for breast, buttock or body contouring, and injectable liquid silicone is not approved for any aesthetic filling use.

And “lipo” or lipotropic (MIC) vitamin injections are not FDA-approved for weight loss; the injectable vitamin B12 (cyanocobalamin) label lists only B12-deficiency uses — not weight loss, fat burning or energy.

The fourth category does not freeze or heat fat; it contracts muscle with high-intensity focused electromagnetic energy (HIFEM).

The BTL 799-2 (K180813), from the HIFEM device family BTL markets as Emsculpt, was cleared on June 14, 2018 as a powered muscle stimulator, for improvement of abdominal tone, strengthening of the abdominal muscles, development of a firmer abdomen, and strengthening, toning and firming of the buttocks and thighs; later clearances added the arms (October 2018) and calves (July 2019).

Those original clearances are for muscle, and they do not include a fat-reduction indication.

One caveat: FDA's 510(k) documents list model numbers, not brand names.

Matching the BTL 799 family to Emsculpt and the BTL-899 family below to Emsculpt NEO is inferred from BTL being the applicant, the device type and the timing.

The fat claim belongs to a different device family: BTL-899 (K192224, cleared December 5, 2019), marketed as Emsculpt NEO, which combines RF with HIFEM and is cleared for non-invasive lipolysis (breakdown of fat) and circumference reduction of the abdomen, originally for skin types I–III only; later versions added the thighs and expanded to skin types I–VI.

BTL says an Emsculpt NEO session lasts 30 minutes and that the typical protocol is four sessions 5 to 10 days apart, for patients up to a BMI of 35.

BTL advertises results of “25% muscle growth” and “30% fat reduction” — manufacturer marketing figures from its own studies, not expected results.

One published study is small but exists: a 2019 MRI study of 22 people who had four abdominal treatments reported an average 18.6% reduction in fat thickness, a 15.4% increase in rectus abdominis thickness and a 10.4% reduction in abdominal separation at 2 months, with 3.8 cm of average waist reduction.

It was a small, single-arm study, so read those numbers as what it measured, not a promise.

The cleared and approved uses decide which option can even be discussed for each area; a use outside them is off-label.

• Belly and flanks (“muffin top”, “love handles”): fat freezing is cleared for the abdomen and flanks at a BMI of 30 or less; SculpSure's first clearance was the flanks; Emsculpt NEO is cleared for abdominal lipolysis and circumference reduction, and the Emsculpt-type clearances cover abdominal tone. No injection this page covers is approved for belly or flank fat — Kybella's label says it is not approved for fat outside the submental region.
• Arms: freezing is cleared for the upper arm (BMI 30 or less), the Emsculpt-type clearances cover the arms for muscle, and Emsculpt NEO's upper-arm clearance carries extra limits — skin types II–III at a BMI of 30 or under.
• Thighs, bra fat, back fat and banana roll: the fat-freezing clearance names all four areas at a BMI of 30 or less; the muscle clearances cover thighs and buttocks; Emsculpt NEO added thighs in 2021.
• Under the chin: the two options this page covers with FDA paperwork are Kybella, approved for moderate to severe submental fullness in adults, and CoolSculpting Elite, cleared for the submental and submandibular areas up to a BMI of 46.2 — the CoolSculpting clearance also says the device can affect the appearance of lax submental tissue. We found no head-to-head trials comparing the two, and Kybella's label reports results on rating scales rather than as a percent of fat removed, so no like-for-like percentage comparison exists.

For the full picture across the body, our body contouring guide compares the categories at the treatment level.

There is no honest national price list for this page to quote.

The one category-wide figure comes from ASPS: an average fee of $1,157 for nonsurgical fat reduction, a category that includes cryolipolysis, Kybella, radiofrequency and laser lipolysis.

That is the average fee reported by ASPS member surgeons in the latest ASPS statistics — not a med spa price, and it excludes related expenses.

Beyond it, our research found no published national list price for a CoolSculpting cycle on any public manufacturer page, and we could not confirm one for Kybella in the sources for this page either.

No FDA document or professional-body source we read gives a standard number of cycles or sessions per area — the provider's treatment plan sets that.

What drives the total shows up in the session counts: cryolipolysis usually 2 sessions, ultrasound 1 to 3 and radiofrequency 4 to 10 (AAD figures), and Kybella up to 6 treatments at least 1 month apart (the label's maximum).

More sessions, more areas, and repeat courses all scale the price.

On results, the AAD's comparison with liposuction is blunt: with non-invasive fat removal the results are subtle — the AAD's phrase is “pants a little looser” — while liposuction delivers more dramatic results.

On whether results last, the AAD says fat cells destroyed by these treatments do not come back, but the remaining fat cells in the area can still expand with weight gain.

We don't have a provider directory to link from this page yet, so the practical answer is a checklist you control.

Ask which device or drug the clinic uses for your area, and have them point to the cleared or approved areas for it — the clearance or label, not a brochure, decides what a treatment is for.

Ask who will perform or operate it and under whose supervision, and how that maps to your state's rules.

AmSpa, the med spa trade association, says injecting botulinum toxin falls under the practice of medicine because an FDA legend (prescription) drug is being used on living tissue, so it must be done by a physician, an independent-practice NP or another licensed professional acting within their scope, under rules that vary by state — ask the same question of any prescription injection, Kybella included.

Then use our 10-point checklist for choosing a med spa before you book anything.